BioSpace News Archive

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, and Blueprint Genetics announced today that they will present results of 10 studies at the virtual 2021 American College of Medical Genetics and Genomics (ACMG) Annual Meeting, to be held April 13–16, 2021.

With Lyme disease season breaking out across the United States, Quidel Corporation announced today that it has partnered with the Bay Area Lyme (BAL) Foundation to help heighten public awareness to this alarming health condition that afflicts as many as 400,000 Americans each year. Quidel is the nation’s leading developer of rapid Lyme disease testing.

n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients living with ultra-rare diseases, today announced a new partnership with ChemGenes Corporation, a biotechnology company providing unparalleled expertise in the field of DNA/RNA synthesis for more than 40 years.

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.

Founded in 2018 to design topical treatments for complex pain, AlgoTherapeutix is developing ATX01 in Chemotherapy-Induced Peripheral Neuropathy

AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into an agreement with PPD, Inc. (NASDAQ: PPD ), a leading global contract research organization (CRO), for its planned Phase 1b/2a clinical trial

Recently Commenced Patient Enrollment in Phase 1/2 CAReS Study of ART27.13 in the UK Reported Positive Pre-Clinical Data Associated with Artelo’s Proprietary CBD Cocrystal $11.2 Million of Cash and Cash Equivalents and Marketable Securities as of February 28, 2021

Resonant Inc., a provider of radio frequency filter solutions developed on a robust intellectual property platform, designed to connect People and Things, has provided a preliminary corporate update for the three months ended March 31, 2021.

For more than a year since the global pandemic began, public temperature screenings among large numbers of people have become the norm in assessing symptoms and limiting the spread of coronavirus.

Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for AK-OTOF, a gene therapy intended for the treatment of otoferlin gene-mediated hearing loss.